Active	Status	Sponsor type	Region	Phase	Filter
4 Active 1 Inactive 5 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Cherian, Bindu
RASolute 302, NCT06625320: Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)	Recruiting	3	460	US	RMC-6236, Gemcitabine, nab-paclitaxel, Irinotecan, Liposomal irinotecan, 5-fluorouracil, leucovorin, Oxaliplatin	Revolution Medicines, Inc.	Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma	06/26	12/27
BOLD-100-001, NCT04421820 / 2022-003079-41: BOLD-100 in Combination with FOLFOX for the Treatment of Advanced Solid Tumours	Recruiting	1/2	220	Europe, Canada, US, RoW	BOLD-100 in combination with FOLFOX Chemotherapy (Dose Expansion), BOLD-100 in combination with FOLFOX Chemotherapy (Dose Escalation)	Bold Therapeutics, Inc., Bold Therapeutics, Inc. (Bold)	Colorectal Cancer, Pancreatic Cancer, Gastric Cancers, Cholangiocarcinoma	06/26	09/26
NCT05270213: Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors	Recruiting	1	64	US	RBS2418, Pembrolizumab	Riboscience, LLC., Oncobay Clinical, Inc	Advanced Cancer	09/25	10/25
Etheridge, Lia
No trials found
Davis, Sa-Heim
No trials found